Comparative Pharmacology
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus R GENE 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus R GENE 10.
MERETEK UBT KIT (W/ PRANACTIN) vs R-GENE 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
Arginine is a semi-essential amino acid that serves as a substrate for nitric oxide (NO) synthesis via nitric oxide synthase (NOS), leading to vasodilation. It also stimulates growth hormone release and is involved in the urea cycle for ammonia detoxification.
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
10 mg intravenously over 1-2 minutes, once daily for 5 days, repeat course after 2-3 weeks if needed.
None Documented
None Documented
Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose.
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-18 hours in renal impairment.
Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination.
Primarily renal (approximately 80-90% unchanged). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent